Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain was written by Garcia, Monica;Llorente, Virginia;Garriga, Lourdes;Christmann, Ute;Rodriguez-Escrich, Sergi;Virgili, Marina;Fernandez, Begona;Bordas, Magda;Ayet, Eva;Burgueno, Javier;Pujol, Marta;Dordal, Albert;Portillo-Salido, Enrique;Gris, Georgia;Vela, Jose Miguel;Almansa, Carmen. And the article was included in Journal of Medicinal Chemistry in 2021.SDS of cas: 175205-82-0 This article mentions the following:
A new series of propionamide derivatives was developed as dual μ-opioid receptor agonists and σ1 receptor antagonists. Modification of a high-throughput screening hit originated a series of piperazinylcycloalkylmethyl propionamides, which were explored to overcome the challenge of achieving balanced dual activity and convenient drug-like properties. The lead compound identified, 18g (I), showed good analgesic effects in several animal models of both acute (paw pressure) and chronic (partial sciatic nerve ligation) pain, with reduced gastrointestinal effects in comparison with oxycodone. In the experiment, the researchers used many compounds, for example, 2-Bromo-3-(trifluoromethyl)pyridine (cas: 175205-82-0SDS of cas: 175205-82-0).
2-Bromo-3-(trifluoromethyl)pyridine (cas: 175205-82-0) belongs to pyridine derivatives. Pyridine has a dipole moment and a weaker resonant stabilization than benzene (resonance energy 117 kJ·mol−1 in pyridine vs. 150 kJ·mol−1 in benzene). Pyridine groups exist in countless molecules, and their applications include catalysis, drug design, molecular recognition, and natural product synthesis.SDS of cas: 175205-82-0